Maze Therapeutics, Inc.
$26.84
▼
-1.17%
2026-04-21 08:03:00
www.mazetx.com
NGM: MAZE
Explore Maze Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.4 B
Current Price
$26.84
52W High / Low
$53.65 / $7.16
Stock P/E
—
Book Value
$7.2
Dividend Yield
—
ROCE
-38.15%
ROE
-47.52%
Face Value
—
EPS
$-3.05
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
141
Beta
—
Debt / Equity
6.57
Current Ratio
15.5
Quick Ratio
15.5
Forward P/E
-7.33
Price / Sales
—
Enterprise Value
$1.01 B
EV / EBITDA
-7.17
EV / Revenue
—
Rating
Strong Buy
Target Price
$64.82
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Geron Corporation | $1.56 | — | $1.02 B | — | -11.23% | -32.99% | $2.01 / $1.04 | $0.35 |
| 2. | PMV Pharmaceuticals, Inc. | $1.43 | — | $73.59 M | — | -81.99% | -55.37% | $1.88 / $0.81 | $1.96 |
| 3. | Satellos Bioscience Inc. | $7.83 | — | $248.1 M | — | -95.23% | -66.37% | $18.98 / $6.24 | $1.8 |
| 4. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 5. | XORTX Therapeutics Inc. | $2.25 | — | $4.16 M | — | -156.2% | -98% | $9.85 / $2.42 | $0.3 |
| 6. | MediciNova, Inc. | $1.47 | — | $71.37 M | — | -31.77% | -25.5% | $1.96 / $1.17 | $0.84 |
| 7. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -38.06 M | -32.97 M | -36.47 M | -35.4 M | -29.73 M | — |
| Net Profit | -34.57 M | -30.09 M | -33.68 M | -32.79 M | -29.58 M | — |
| EPS in Rs | -0.7 | -0.61 | -0.68 | -0.66 | -0.6 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 167.5 M | 0 M | 0 M |
| Operating Profit | -142.9 M | 57.59 M | -98.55 M | -111.03 M |
| Net Profit | -131.12 M | 52.23 M | -100.42 M | -114.94 M |
| EPS in Rs | -2.64 | 1.05 | -2.02 | -2.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 397.13 M | 240.54 M | 71.5 M | 149.96 M |
| Total Liabilities | 42.16 M | 551.73 M | 445.35 M | 432.42 M |
| Equity | 354.97 M | -311.18 M | -373.85 M | -282.46 M |
| Current Assets | 349.72 M | 201.67 M | 34.11 M | 106.15 M |
| Current Liabilities | 22.56 M | 20.67 M | 16.32 M | 20.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -111.94 M | 75.95 M | -86.83 M | -99.2 M |
| Investing CF | -170.96 M | -1.15 M | -0.44 M | -3.17 M |
| Financing CF | 275.34 M | 92.85 M | 16.39 M | 1.73 M |
| Free CF | -112.73 M | 74.81 M | -87.27 M | -101.17 M |
| Capex | -0.79 M | -1.15 M | -0.44 M | -1.97 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | — | — |
| Earnings Growth % | -351.04% | 152.02% | 12.64% | — |
| Profit Margin % | — | 31.18% | — | — |
| Operating Margin % | — | 34.38% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | 36.35% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.